MedTrace Logo

Study of Chemotherapy Side Effects in Cancer Patients: Non-invasive Optical Measurements of the Brain

NCT01277276 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-11-01

No results posted yet for this study

Summary

Currently there is no methodology that can assign a risk of development of chemo brain and thus, studies to understand how and why only some patients develop chemo brain along with studies of potential treatments face major hurdles. This study will define hemodynamic/optical parameters in normal individuals and cancer patients undergoing chemotherapy potentially identifying optical parameters that are associated with the development of chemo brain, leading to new insights into the origin of the chemo brain condition, and importantly potentially identifying parameters that may predict who will develop "chemo brain" in order to directing investigations of therapies.

Conditions

  • Signs and Symptoms

Interventions

DEVICE

Diffuse optical spectroscopy and Near infrared spectroscopy

Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.

Sponsors & Collaborators

  • Beckman Laser Institute University of California Irvine

    collaborator OTHER

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Edward Nelson, MD · Beckman Laser Institute University of California Irvine

  • Bruce Tromberg, PhD · Beckman Laser Institute University of California Irvine

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2013-02-28
Completion
2013-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01277276 on ClinicalTrials.gov